Abstract:Objective:To evaluate the safety and efficacy of modified percutaneous transhepatic portal vein islet cell transplantation.Methods:Clinical data of 46 patients undergoing percutaneous transhepatic portal vein islet cell transplantation in Shanghai Changzheng Hospital Affiliated to Naval Medical University from December 2016 to June 2020 were retrospectively analyzed. Among them, 34 patients were male and 12 female, aged from 13 to 74 years, with a median age of 49 years. The informed consents of all patients were obtained and the local ethical committee approval was received. According to different surgical methods, all patients were divided into the conventional intervention group (conventional group, n=25) and modified intervention group (modified group, n=27). In the conventional group, infusion of islet cells was performed with F single-curved arteriographic catheter under real-time pressure monitoring, and the puncture channel was blocked up with steel ring and gelfoam particles. In the modified group, PTCD catheter infusion with manually-cutted inner core was performed under intermittent pressure monitoring, and the puncture channel was blocked up with gelfoam particles. The operation time and portal pressure between two groups were compared by using t test and the rate comparison was analyzed by Chi-square test.Results:46 patients successfully completed 52 times of islet cell transplantation, with a success rate of 100%. Among them, 2 recipients received twice transplantation in the conventional group and 4 in the modified group. The operation time in the conventional and modified group was (124±14) and (110±17) min, respectively, where no significant difference was observed (t=1.35,P>0.05). In the conventional group, the portal vein pressure before and after transplantation were (13±4) and (12±3) mmHg (1 mmHg=0.133 kPa), and (16±3) and (14±5) mmHg in the modified group, where no significant difference was observed between portal vein pressures before and after operation (t=0.34, 0.87;P>0.05). 1 case developed postoperative thoracic hemorrhage in the conventional group and 1 case of intrahepatic hematoma in the modified group, and both were healed after conservative treatments. The incidence of bleeding was 4%(1/25) and 4%(1/27) respectively in the conventional and modified groups, with no significant difference (χ2=0.45,P>0.05). The insulin-free rate in the recipients undergoing initial islet cell transplantation within 6 months was 60%(15/25) and 66%(18/27) respectively in the conventional and modified groups, with no significant difference (χ2=5.32,P>0.05). In the conventional and modified groups, the fasting C-peptide increment was (0.22±0.07) and (0.19±0.06) nmol/L, respectively, and the 2 h postprandial C-peptide increment was (0.67±0.20) and (0.53±0.17) nmol/L, respectively, with no significant differences (t=1.362, 1.722;P>0.05).Conclusions:Compared with the conventional surgery, the modified percutaneous transhepatic portal vein islet cell transplantation is equally safe and efficacious, which possess multiples advantages of less use of intrahepatic steel ring and no artifacts in the postoperative imaging examination.

Pancreatic Islet Transplantation for 3 Cases of Graft Failure after Pancreatic Transplantation

Simultaneous pancreas-kidney transplantation: a report of 5 cases

[Early Efficacy of Islet Transplantation in the Treatment of Adult Advanced Diabetes].

Clinical study of surviving in simultaneous pancreas-kidney transplantation

Clinical Researches on Islet Transplantation in 20 Patients with Insulin-Dependent Diabetes Mellitus

Allograft Islet Cell Transplantation and Postoperatively Modified Edmonton Protocol for 3 Cases of Type 1 Diabetes Mellitus

The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions

Pancreatic islet transplantation: current advances and challenges

The Influences of Islet Transplantation on Metabolic Abnormalities and Diabetic Complications.

Pancreas islet transplantation into the capsule of kidney for the treatment of type I diabetes mellitus

Phase 3 trial of human islet‐after‐kidney transplantation in type 1 diabetes

Ultrasound-Guided Human Islet Transplantation: Safety, Feasibility, and Efficacy Analysis.

Safety and efficacy of modified percutaneous transhepatic portal vein islet cell transplantation

Pancreas transplantation for diabetes mellitus

Islet Alone Versus Islet after Kidney Transplantation: Metabolic Outcomes and Islet Graft Survival

Clinical Progress of Islet Transplantation to Cure Type 1 Diabetes Mellitus

Combined Laparoscopic spleen-preserving distal pancreatectomy and autologous islet transplantation: report of one case and literature review

Transplantation of allogeneic pancreatic islets and pancreatic stem cells-derived islet-like structures to treat diabetes

Long-Term Efficacy of Simultaneous Pancreas and Kidney Transplantation in Liver Transplant Recipient.

Islet graft survival and function: concomitant culture and transplantation with vascular endothelial cells in diabetic rats.

Pancreas transplantation: review